Genetic signature trumps clinicopathological features

Genetic signature trumps clinicopathological features

Play all audios:

Loading...

Access through your institution Buy or subscribe Many women treated with adjuvant chemotherapy for breast cancer do not derive significant benefit. Several genomic classifiers, such as MammaPrint®, have been developed to improve prognostic accuracy. A prospective study by Sabine Linn _ et al_. has shown that MammaPrint improves prognostic accuracy over traditional clinicopathological features in the clinical setting. Linn explains, “we wanted to know whether it was feasible to use the MammaPrint test in community hospitals in the Netherlands, and whether its prognostic value would be retained when used prospectively.” The researchers chose an observational approach as it allowed them to study the use of the MammaPrint test in daily clinical practice. A substantial portion of patients with low-risk disease based on the MammaPrint result did not receive chemotherapy even though AdjuvantOnline! clinicopathological risk estimations indicated therapy. “Compared to AdjuvantOnline! risk estimations (with high risk defined as <90% 10-year survival), 20% fewer patients were labelled high risk according to MammaPrint,” points out Linn. Moreover, 70 patients deemed high risk by AdjuvantOnline!, but low risk by MammaPrint and who had not received any systemic therapy had a 100% distant-recurrence free interval probability at 60 months of follow-up. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support ORIGINAL RESEARCH PAPER * Drukker, C. A. _ et al_. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. _Int. J. Cancer_ doi:10.1002/ijc.28082 Article  CAS  Google Scholar  Download references Authors * Lisa Hutchinson View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Hutchinson, L. Genetic signature trumps clinicopathological features. _Nat Rev Clin Oncol_ 10, 184 (2013). https://doi.org/10.1038/nrclinonc.2013.27 Download citation * Published: 19 February 2013 * Issue Date: April 2013 * DOI: https://doi.org/10.1038/nrclinonc.2013.27 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

Access through your institution Buy or subscribe Many women treated with adjuvant chemotherapy for breast cancer do not derive significant benefit. Several genomic classifiers, such as


MammaPrint®, have been developed to improve prognostic accuracy. A prospective study by Sabine Linn _ et al_. has shown that MammaPrint improves prognostic accuracy over traditional


clinicopathological features in the clinical setting. Linn explains, “we wanted to know whether it was feasible to use the MammaPrint test in community hospitals in the Netherlands, and


whether its prognostic value would be retained when used prospectively.” The researchers chose an observational approach as it allowed them to study the use of the MammaPrint test in daily


clinical practice. A substantial portion of patients with low-risk disease based on the MammaPrint result did not receive chemotherapy even though AdjuvantOnline! clinicopathological risk


estimations indicated therapy. “Compared to AdjuvantOnline! risk estimations (with high risk defined as <90% 10-year survival), 20% fewer patients were labelled high risk according to


MammaPrint,” points out Linn. Moreover, 70 patients deemed high risk by AdjuvantOnline!, but low risk by MammaPrint and who had not received any systemic therapy had a 100%


distant-recurrence free interval probability at 60 months of follow-up. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution


Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full


article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *


Contact customer support ORIGINAL RESEARCH PAPER * Drukker, C. A. _ et al_. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. _Int. J.


Cancer_ doi:10.1002/ijc.28082 Article  CAS  Google Scholar  Download references Authors * Lisa Hutchinson View author publications You can also search for this author inPubMed Google Scholar


RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Hutchinson, L. Genetic signature trumps clinicopathological features. _Nat Rev Clin Oncol_ 10, 184


(2013). https://doi.org/10.1038/nrclinonc.2013.27 Download citation * Published: 19 February 2013 * Issue Date: April 2013 * DOI: https://doi.org/10.1038/nrclinonc.2013.27 SHARE THIS ARTICLE


Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard


Provided by the Springer Nature SharedIt content-sharing initiative